Does the ISCHEMIA Trial Apply to My Patients?

Area of Science:

• Cardiology
• Interventional Cardiology
• Clinical Trials

Background:

• Contemporary guideline-directed medical therapy significantly impacts coronary artery disease prognosis.
• The ISCHEMIA trial investigated revascularization versus optimal medical therapy in stable coronary artery disease.
• Uncertainty exists regarding the generalizability of ISCHEMIA trial findings to real-world settings.

Purpose of the Study:

• To assess the relevance of the ISCHEMIA trial's findings on myocardial infarction or death in patients with stable coronary disease and moderate or large ischemia territory.
• To evaluate whether invasive revascularization provides benefits beyond optimal medical therapy in this patient group.
• To determine the applicability of ISCHEMIA and ISCHEMIA-CKD trials in real-world outcomes.

Main Methods:

• The ISCHEMIA trial was a randomized controlled trial.
• It compared invasive revascularization with optimal medical therapy.
• Participants had stable coronary artery disease and moderate or large ischemia territory.

Main Results:

• No significant difference in myocardial infarction or death was observed between the invasive revascularization and optimal medical therapy groups.
• Observational data suggest limited generalizability of the ISCHEMIA trial to diverse populations.
• Further studies are needed to validate these findings.

Conclusions:

• The ISCHEMIA trial did not show a benefit of invasive revascularization over optimal medical therapy for stable coronary artery disease patients with moderate to severe ischemia.
• The real-world applicability and generalizability of the ISCHEMIA and ISCHEMIA-CKD trials require further investigation.
• Optimal therapy modality for stable coronary artery disease with moderate or severe ischemia needs continued evaluation.